# A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

> **NCT01243762** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 47 (actual)

## Conditions studied

- Neoplasms Malignant

## Interventions

- **DRUG:** dalotuzumab
- **DRUG:** MK-0752
- **DRUG:** ridaforolimus
- **DRUG:** MK-2206

## Key facts

- **NCT ID:** NCT01243762
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-11-22
- **Primary completion:** 2012-12-04
- **Final completion:** 2013-03-25
- **Target enrollment:** 47 (ACTUAL)
- **Why stopped:** The study was terminated for business reasons and not due to any safety or efficacy concerns related to dalotuzumab.
- **Last updated:** 2018-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01243762

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01243762, "A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01243762. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*